Peter G. Linde

Corporate Officer/Principal chez Walden Biosciences, Inc.

57 ans

Health Technology

Finance

Health Services

Postes actifs de Peter G. Linde

Sociétés	Poste	Début	Fin
Walden Biosciences, Inc. Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Walden Biosciences, Inc. provides renal therapeutics services. The company is headquartered in Cambridge, MA.	Corporate Officer/Principal	11/10/2022	-

Sociétés	Poste	Début	Fin
MORPHIC HOLDING, INC.	Directeur Technique/Scientifique/R&D	17/03/2020	31/12/2021
FIBROGEN, INC.	Corporate Officer/Principal	-	-
ACCELERON PHARMA INC.	Corporate Officer/Principal	-	-

Massachusetts Institute of Technology

Undergraduate Degree

Internationale

Etats-Unis

Opérationnelle

Corporate Officer/Principal	3
Chief Tech/Sci/R&D Officer	1
Undergraduate Degree	1

Sectorielle

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	2
MORPHIC HOLDING, INC.	Health Technology
FIBROGEN, INC.	Health Technology

Entreprise privées	2
Acceleron Pharma, Inc. Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.	Health Technology
Walden Biosciences, Inc. Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Walden Biosciences, Inc. provides renal therapeutics services. The company is headquartered in Cambridge, MA.	Health Services

Entreprise privées

Health Technology

Health Services